Introduction
============

According to the American Cancer Center, there were about 234,030 newly diagnosed lung cancer patients in 2018, of which more than 80% had non-small cell lung cancer (NSCLC)[@B1],[@B2]. Early-stage lung cancer patients account for 16% of newly diagnosed cases, diagnosed according to the criteria of the American Joint Commission for Cancer stage I or II disease[@B3]. Currently, surgery is the gold standard for treatment of early-stage NSCLC[@B4]. However, \>20% of patients with early-stage NSCLC are ineligible for surgery because of various factors such as old age, severe impairment of lung function, or other comorbidities[@B5]. Therefore, viable alternatives, including ablation and SBRT, have been emerging to achieve reliable local control in such patients[@B6],[@B7]. Three-year local control rates of up to 90% were observed on application of SBRT for early-stage lung cancer[@B6],[@B8]. Ablation, including laser ablation, cryotherapy, electrocautery, and fulguration, is an image-guided technique[@B9]. Good local-regional control has been reported with ablation, compared to that with SBRT, for patients with inoperable NSCLC[@B10],[@B11]. To date, no large population-based studies have been performed using a cancer database to compare clinical outcomes between ablation and SBRT cohorts. In addition, there have been no randomized studies or prospective trials for assessing the effectiveness of the two treatments. The purpose of this study was to compare survival rates between patients with stage IA NSCLC treated with ablation and SBRT using the Surveillance, Epidemiology, and End Results (SEER) database.

Patients and Methods
====================

Data Source
-----------

The data used in this study were extracted from the SEER database. The SEER database is sponsored by the US National Cancer Institute and collects registry information, including that of patient survival, pathological type, disease stage, and treatment. The SEER database was established in 1973 and contains data of approximately 10% of the US population.

Study Population
----------------

We limited the cohort to patients diagnosed with stage IA NSCLC (tumor size ≤3 cm) between 2004 and 2015. All included patients were inoperable and underwent SBRT or ablation (including laser ablation, cryotherapy, electrocautery, and fulguration). Complete patient information was available in the SEER database.

Covariates
----------

Baseline characteristics were based on 14 covariates, including age, sex, tumor size, race, differentiation grade, tumor location, histologic type, laterality, insurance status, marital status, year of diagnosis, geographic region, education level, and median household income.

Clinicopathological Data
------------------------

According to histologic type, NSCLC cases were classified as follows: (1) squamous cell carcinoma (SQCC) (histologic codes 8052, 8070-8075, 8083, 8084, 8123); (2) adenocarcinoma (AD) (histologic codes 8244, 8245, 8250-8255, 8260, 8290, 8310, 8323, 8333, 8480, 8481, 8490, 8507, 8550, 8570, 8571, 8574, and 8576); and (3) large cell carcinoma (histologic codes 8012-8014). According to the SEER criteria, all 6,395 patients with stage IA NSCLC were classified as having undergone SBRT (using regional treatment modality-specific codes) or ablation, defined as laser ablation/cryotherapy (SEER surgical code 12) and electrocautery/fulguration (includes use of hot forceps for tumor destruction; SEER surgical code 13).

Statistical Analyses
--------------------

All data were analyzed using IBM SPSS, version 20.0 (IBM Corp, Armonk, NY, USA). Kaplan-Meier analysis was performed to compare survival curves between the ablation and SBRT groups. Propensity score methods were used to control for potential differences in the baseline characteristics of the included patients. Cox regression analysis was performed to assess the balance in baseline covariates between the two groups after adjusting for the estimated propensity scores.

Results
=======

Baseline Cohort Characteristics
-------------------------------

A total of 6395 patients with stage IA NSCLC who were treated with SBRT or ablation as primary treatment from 2004 to 2015 were identified. The number of patients who received SBRT and ablation were 6004 (93.89%) and 391(6.11%), respectively. Table [1](#T1){ref-type="table"} shows the baseline characteristics of all patients, identified through the SEER database. Kaplan-Meier analyses demonstrated significant differences in overall survival (OS) between the two groups according to sex (*p*\<0.001), age (p\<0.001), tumor size (*p*\<0.001), histologic type (*p*\<0.001), differentiation grade (p\<0.001), insurance status (*p*\<0.001), year of diagnosis (*p*\<0.001), and geographic region (*p*=0.002). However, no significant differences in OS were observed with respect to race (*p*=0.080), tumor location (*p*=0.062), laterality (*p*=0.734), marital status (p=0.340), education level (*p*=0.425), and median household income (*p*=0.531) (Table [1](#T1){ref-type="table"}).

Comparison of Disease-specific Mortality and Median Survival between the SBRT and Ablation Groups
-------------------------------------------------------------------------------------------------

The overall lung cancer-specific mortality rate in patients with stage IA NSCLC was 29.5% (1886/6395). The mortality rates were 29.0% (1739/6004) and 37.6% (147/391) in the SBRT and ablation groups, respectively. The overall median survival of patients with stage IA NSCLC was 20 months. The median survival in the SBRT and ablation groups were 20 and 31 months, respectively (Table [2](#T2){ref-type="table"}). Compared to the SBRT group, the crude hazard ratio (HR) (95% confidence interval \[CI\]) was 0.931 (0.821-1.055, *p*=0.260) for patients with stage IA NSCLC in the ablation group. In patients with stage IA SQCC, the HR (95% CI) was 0.877 (0.684-1.124, *p*=0.299) in the ablation group, compared to the SBRT group. In patients with stage IA AD, the HR (95% CI) in the ablation group was 0.919 (0.768-1.099, *p*=0.353), compared to the SBRT group (Table [3](#T3){ref-type="table"}).

Kaplan-Meier Analysis of Survival Curves between the SBRT and Ablation Groups
-----------------------------------------------------------------------------

No significant differences in survival curves were observed between the SBRT and ablation groups on Kaplan-Meier analysis, as shown in Figure [1](#F1){ref-type="fig"}. Among patients with stage IA NSCLC, survival (log-rank *p*\>0.05) was similar in the ablation and SBRT groups (Figure [1](#F1){ref-type="fig"}A). Consistently, no significant differences in survival were observed between the two subtypes of NSCLC: SQCC (log-rank *p*\>0.05) (Figure [1](#F1){ref-type="fig"}B) and AD (log-rank *p*\>0.05) (Figure [1](#F1){ref-type="fig"}C). Our data demonstrated similar effects on survival of patients with stage IA SQCC and AD in the SBRT and ablation groups.

Comparison of the Effects on Survival of Patients with Stage IA NSCLC between the SBRT and Ablation Groups
----------------------------------------------------------------------------------------------------------

No significant differences (*p*=0.260) in the OS of patients with stage IA NSCLC were observed between the SBRT and ablation groups on univariate analysis (Table [3](#T3){ref-type="table"}). Furthermore, no significant differences were observed in the OS of patients with stage IA SQCC (*p*=0.299) and AD (*p*=0.353) between the two groups (Table [3](#T3){ref-type="table"}). A Cox model with nine variables, including sex, age, differentiation grade, tumor size, histologic type, insurance status, year of diagnosis, geographic region, and treatment, showed an HR (95% CI) of 0.930 (0.817-1.058, *p*=0.269) on comparing between the ablation and SBRT groups (Table [4](#T4){ref-type="table"}). Then the following variables were excluded: insurance status, year of diagnosis, and geographic region (these covariates were not very close to the clinic), and a new Cox model was adjusted for age, sex, tumor size, differentiation grade, histologic type, and treatment.

In this model, the HR (95% CI) was 0.974 (0.858-1.105, p=0.680) on comparing between the ablation and SBRT groups (Table [5](#T5){ref-type="table"}). These results indicated that no significant difference was observed between the effect of SBRT and ablation on the OS of patients with stage IA NSCLC.

Discussion
==========

As some elderly patients with cardiopulmonary insufficiency or other comorbidities are not eligible for surgical treatment, non-invasive options, such as SBRT and ablation, have played an increasingly important role in the treatment of NSCLC[@B12],[@B13]. Currently, no large-scale clinical trials have compared the therapeutic effect between ablation and SBRT and no independent cohorts which can be downloaded from publicly available databases to validate our main findings and conclusions, primarily owing to the novelty and limitations associated with the practical application of ablation treatment. Recently, Johannes Uhlig[@B11] conducted a retrospective study and reported that the estimated 1-, 3-, and 5-year OS rates of patients treated with ablation were comparable to those of patients treated with SBRT (1-year, 85.4% vs. 86.3%,*p*=0.76; 3-year, 47.8% vs. 45.9%, *p*=0.32; 5-year, 24.6% vs. 26.1%, *p*=0.81). These results were similar to our findings. According to our study, no significant survival difference was seen on analyzing a large SEER dataset, which contained the information of patients diagnosed with stage IA NSCLC during 2005-2014. Our results provide a curative reference on the non-inferior survival benefits achieved with ablation as primary treatment for stage IA NSCLC.

At present, it is widely accepted that SBRT is the optimal curative approach for medically inoperable patients[@B14]. SBRT can reach occult regional and deep structures that are difficult to explore via surgery, resulting in prolonged survival. However, SBRT has a drawback; SBRT is associated with poor control of local pulmonary lesions or multiple metastatic disease, increasing the risk of cancer-specific death. Pneumonitis, dyspnea, and chest pain were most commonly reported adverse events associated with SBRT[@B15], usually occurring approximately 4-12 weeks after treatment, in a systematic review[@B16],[@B17]. The incidence of toxicities induced by SBRT was higher in patients with central lung cancer (close to the airway) than in those with peripheral lung cancer[@B18],[@B19]. In addition, patients with advanced age or multiple comorbidities tend to forego definitive treatment; this is one of the predominant reasons why the systemic adverse reactions of SBRT commonly appear gradually over long-term treatment. and would not become new detective reflection factors within 30 days of readmission to hospital[@B18]. Relatively, complications of ablation usually occur on the same day or within a few days of treatment; of these adverse events, self-limiting pneumothorax is the most common[@B10],[@B20]. The majority of patients can experience relief after symptomatic treatment, and only a small proportion of patients (10%-30%) need to undergo chest tube placement[@B20],[@B21]. Other rare complications of ablation include pulmonary hemorrhage[@B22],[@B23], air embolism[@B24],[@B25], pleural effusion[@B26], bronchopleural fistula formation[@B27], bronchospasm[@B10], and sometimes even death[@B7]. Considering the similarity in survival rates, fewer complications and better quality of life may be the main factors influencing the choice between SBRT and ablation for inoperable patients with stage IA NSCLC. This will be a direction for future research.

Although the SEER database provides a significant data-collecting platform for addressing this urgent issue, this investigation has some limitations. Although we conducted accurate matching of cohorts, this study was retrospective in nature; thus, the factors not included in the matching process may be responsible for the observed differences in outcome. In addition, OS was analyzed without any adjustment for radiation dose, toxicities, pulmonary function, cause of death, and local progression-free survival. Furthermore, the SEER database does not provide details regarding repetitive ablation treatments and feasible approaches, such as surgical, percutaneous, and bronchoscopic ablation. Therefore, further research is needed on this topic.

Due to its retrospective design, our study has some limitations. For example, the lack of original datum from our own studies as well as validation for main findings and conclusion. Nevertheless, with the inclusion of 15 variables and nearly 6400 patients in our cohort, the present study represents a well-balanced analysis of Ablation or SBRT treatment methods. Thus, in the absence of data from prospective trials, our findings can provide information that is useful for the management in inoperable patients with stage IA NSCLC.

Conclusion
==========

According to the results of our study, no significant difference was observed in survival between inoperable patients with stage IA NSCLC who were treated with SBRT and ablation. Therefore, the quality of life after SBRT or ablation may be the main consideration for choosing the treatment method.
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###### 

Baseline Characteristics of Patients with Stage IA NSCLC Treated with SBRT and Ablation in the SEER Program, 2004-2015

  ------------------------------------------------------------------------------------------------------
  Characteristics                             NSCLC   SBRT    Ablation   \                     
                                                                         *p*                   
  ------------------------------------------- ------- ------- ---------- ------- ----- ------- ---------
  Age, year                                                                                    \<0.001

  \<45                                        6       0.1     6          0.1     0     0       

  ≥45, \<55                                   119     1.9     110        1.8     9     2.3     

  ≥55, \<65                                   785     12.3    730        12.2    55    14.1    

  ≥65, \<75                                   2090    32.7    1964       32.7    126   32.2    

  ≥75                                         3395    53.0    3194       53.2    201   51.4    \<0.001

  Sex                                                                                          

  Female                                      3607    56.4    3387       56.4    220   56.3    

  Male                                        2788    43.6    2617       43.6    171   43.7    0.080

  Race                                                                                         

  White                                       5331    83.4    5156       85.9    175   44.7    

  Black                                       776     12.1    574        9.6     202   51.7    

  Others                                      279     4.4     265        4.4     14    3.6     

  Unknown                                     9       0.1     9          0.1     0     0       \<0.001

  Tumor size, cm                                                                               

  ≤1                                          325     5.1     272        4.5     53    13.6    

  \>1, ≤2                                     3135    49.0    2926       48.7    209   53.5    

  \>2, ≤3                                     2917    45.6    2795       46.6    122   31.2    

  Unknown                                     18      0.3     11         0.2     7     1.7     0.062

  Tumor location                                                                               

  Upper lobe                                  3945    61.7    3715       61.9    230   58.8    

  Middle lobe                                 293     4.6     270        4.5     23    5.9     

  Lower lobe                                  2023    31.6    1892       31.5    131   33.5    

  NOS                                         101     1.6     96         1.6     5     1.3     

  Overlapping lesion                          11      0.2     11         0.2     0     0       

  Main bronchus                               22      0.3     20         0.3     2     0.5     \<0.001

  Differentiated grade                                                                         

  Grade I                                     548     8.6     503        8.4     45    11.5    

  Grade II                                    1054    16.5    994        16.6    60    15.3    

  Grade III                                   1283    20.1    1212       20.2    71    18.2    

  Grade IV                                    35      0.5     33         0.5     2     0.5     

  Unknown                                     3475    54.3    3262       54.3    213   54.5    \<0.001

  Histologic type                                                                              

  Squamous cell carcinoma                     2112    33.0    2017       33.6    95    24.3    

  Adenocarcinoma                              3113    48.7    2897       48.3    216   55.2    

  Large cell carcinoma                        71      1.1     68         1.1     3     0.8     

  Other                                       1099    17.2    1022       17.0    77    19.7    0.734

  Laterality                                                                                   

  Right-origin of primary                     3647    57.0    3418       56.9    229   58.6    

  Left-origin of primary                      2748    43.0    2586       43.1    162   41.4    \<0.001

  Insurance status                                                                             

  Medicaid                                    650     10.2    627        10.4    23    5.9     

  Uninsured                                   32      0.5     30         0.5     2     0.5     

  Unknown                                     813     12.7    705        11.7    108   27.6    

  Insured                                     4900    76.6    4642       77.4    258   66.0    0.340

  Marital status                                                                               

  Married                                     2753    43.0    2582       43.0    171   43.7    

  Single                                      695     10.9    650        10.9    45    11.5    

  Divorced                                    841     13.2    786        13.1    55    14.1    

  Widowed                                     1817    28.4    1707       28.4    110   28.1    

  Unknown                                     280     4.4     270        4.5     10    2.6     

  Unmarried or Domestic Partner               9       0.1     9          0.1     0     0       \<0.001

  Year of diagnosis                                                                            

  2004-2007                                   1013    15.8    866        14.4    147   37.6    

  2008-2011                                   1969    30.8    1814       30.2    155   39.6    

  2012-2015                                   3413    53.4    3324       55.4    89    22.8    0.002

  Geographic region                                                                            

  East                                        2799    43.8    2673       44.6    126   32.2    

  Northwest                                   11      0.2     11         0.2     0     0       

  West                                        2532    39.6    2301       38.3    231   59.1    

  North                                       882     13.7    855        14.2    27    6.9     

  Southwest                                   171     2.7     164        2.7     7     1.8     0.425

  High school education                                                                        

  ≥21                                         841     13.2    758        12.6    83    21.2    

  13-20                                       1933    30.2    1810       30.1    123   31.5    

  7-12                                        3103    48.5    2952       49.2    151   38.6    

  \<7                                         518     8.1     484        8.1     34    8.7     

  Median household income (dollar, in tons)                                                    0.531

  \<38000                                     361     5.6     356        5.9     5     1.3     

  38000-47999                                 1031    16.2    1019       17.0    12    3.1     

  48000-62999                                 2433    38.1    2245       37.4    188   48.1    

  \>63000                                     2570    40.1    2384       39.7    186   47.6    

  Total                                       6395    100.0   6004       100.0   391   100.0   
  ------------------------------------------------------------------------------------------------------

**Abbreviations:** NSCLC, non-small cell lung cancer; SBRT, stereotactic body radiotherapy; NOS, not otherwise specified; SEER: surveillance, epidemiology and end Result.

###### 

Association with Cancer-Specific Mortality and Median Survival Time Among Patient Groups (SEER database, 2004-2015)

  Group      Mortality, n/N (%)   Median survival time (months)
  ---------- -------------------- -------------------------------
  Overall    29.5% (1886/6395)    20
  SBRT       29.0% (1739/6004)    20
  Ablation   37.6% (147/391)      31

**Abbreviations:** SEER, Surveillance, Epidemiology and End Results; SBRT, stereotactic body radiotherapy.

###### 

Univariate Analysis Comparing Patient Survival (*SBRT vs* Ablation)

  Variable   Number   Univariable Analysis                 
  ---------- -------- ---------------------- ------------- -------
  NSCLC      6395     0.931                  0.821-1.055   0.260
  SQCC       2112     0.877                  0.684-1.124   0.299
  AD         3113     0.919                  0.768-1.099   0.353

**Abbreviations:** SBRT, stereotactic body radiotherapy; NSCLC, non-small cell lung cancer; SQCC, Squamous cell carcinoma; AD, Adenocarcinoma; HR, hazard ratio; CI, confidence interval.

###### 

Multivariate Analysis Using a Cox Proportional Hazards Model in Patients with stage IA NSCLC

  Variable                  Multivariable Analysis                   
  ------------------------- ------------------------ --------------- ---------
  Age, year                                                          \<0.001
  \<45                      Reference                                
  ≥45, \<55                 4.020                    0.977 -16.539   0.054
  ≥55, \<65                 4.091                    1.016 -16.466   0.047
  ≥65, \<75                 4.872                    1.213 -19.566   0.026
  ≥75                       5.244                    1.306 -21.054   0.019
  Sex                                                                \<0.001
  Female                    Reference                                
  Male                      1.288                    1.201 -1.380    
  Tumor size, cm                                                     \<0.001
  ≤1                        Reference                                
  \>1, ≤2                   1.110                    0.938 -1.313    0.224
  \>2, ≤3                   1.242                    1.049 -1.471    0.012
  Unknown                   2.655                    1.602 -4.399    \<0.001
  Differentiated grade                                               0.003
  Grade I                   Reference                                
  Grade II                  1.306                    1.114 -1.532    0.001
  Grade III                 1.320                    1.129 -1.542    \<0.001
  Grade IV                  1.211                    0.794 -1.847    0.374
  Unknown                   1.187                    1.028 -1.370    0.019
  Histologic type                                                    \<0.001
  Squamous cell carcinoma   Reference                                
  Adenocarcinoma            0.821                    0.757 -0.891    \<0.001
  Large cell carcinoma      1.190                    0.883 -1.605    0.253
  Other                     0.923                    0.836 -1.018    0.110
  Insurance status                                                   0.001
  Medicaid                  Reference                                
  Uninsured                 0.893                    0.501 -1.592    0.701
  Unknown                   0.871                    0.735 -1.031    0.109
  Insured                   0.782                    0.694 -0.882    \<0.001
  Year of diagnosis                                                  \<0.001
  2004-2007                 Reference                                
  2008-2011                 0.818                    0.722 -0.926    0.002
  2012-2015                 0.738                    0.644 -0.845    \<0.001
  Geographic region                                                  0.005
  East                      Reference                                
  Northwest                 2.282                    1.081 -4.817    0.030
  West                      0.896                    0.830 -0.967    0.005
  North                     0.895                    0.805 -0.995    0.040
  Southwest                 0.901                    0.724 -1.122    0.352
  Treatment                                                          0.269
  SBRT                      Reference                                
  Ablation                  0.930                    0.817 -1.058    

**Notes:** [^a^]{.ul} Multivariate analysis for age, sex, tumor size, tumor location, differentiated grade, histologic type, insurance status, year of diagnosis, geographic region and treatment.

**Abbreviations:** NSCLC, non-small cell lung cancer; NOS, not otherwise specified; HR, hazard ratio; CI, confidence interval; SBRT, stereotactic body radiotherapy.

###### 

Univariable and Multivariable Analyses on OS in Patients with stage IA NSCLC

  Variable                  Univariable analysis   Multivariable analysis ^a^                                         
  ------------------------- ---------------------- ---------------------------- --------- ----------- --------------- ---------
  Age, year                                                                     \<0.001                               0.001
  \<45                      Reference                                                     Reference                   
  ≥45, \<55                 4.020                  0.977 -16.539                0.054     3.443       0.837 -14.158   0.087
  ≥55, \<65                 4.091                  1.016 -16.466                0.047     3.364       0.836 -13.533   0.088
  ≥65, \<75                 4.872                  1.213 -19.566                0.026     3.886       0.968 -15.593   0.056
  ≥75                       5.244                  1.306 -21.054                0.019     4.169       1.039 -16.720   0.044
  Sex                                                                           \<0.001                               \<0.001
  Female                    Reference                                                     Reference                   
  Male                      1.288                  1.201 -1.380                           1.280       1.195 -1.372    
  Tumor size, cm                                                                \<0.001                               \<0.001
  ≤1                        Reference                                                     Reference                   
  \>1, ≤2                   1.110                  0.938 -1.313                 0.224     1.126       0.952 -1.332    0.165
  \>2, ≤3                   1.242                  1.049 -1.471                 0.012     1.283       1.084 -1.519    0.004
  Unknown                   2.655                  1.602 -4.399                 \<0.001   3.035       1.835 -5.018    \<0.001
  Differentiated grade                                                          0.003                                 0.004
  Grade I                   Reference                                                     Reference                   
  Grade II                  1.306                  1.114 -1.532                 0.001     1.307       1.115 -1.533    0.001
  Grade III                 1.320                  1.129 -1.542                 \<0.001   1.324       1.133 -1.546    \<0.001
  Grade IV                  1.211                  0.794 -1.847                 0.374     1.311       0.860 -1.997    0.208
  Unknown                   1.187                  1.028 -1.370                 0.019     1.202       1.042 -1.387    0.012
  Histologic type                                                               \<0.001                               \<0.001
  Squamous cell carcinoma   Reference                                                     Reference                   
  Adenocarcinoma            0.821                  0.757 -0.891                 \<0.001   0.810       0.747 -0.879    \<0.001
  Large cell carcinoma      1.190                  0.883 -1.605                 0.253     1.256       0.931 -1.694    0.135
  Other                     0.923                  0.836 -1.018                 0.110     0.958       0.869 -1.056    0.384
  Treatment                                                                     0.269                                 0.680
  SBRT                      Reference                                                     Reference                   
  Ablation                  0.930                  0.817 -1.058                           0.974       0.858 -1.105    

**Notes:** [^a^]{.ul} Multivariate analysis for age, sex, tumor size, differentiated grade, histologic type, treatment.

**Abbreviations:** OS, overall survival; NSCLC, non-small cell lung cancer; HR, hazard ratio; CI, confidence interval; SBRT, stereotactic body radiotherapy.
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